These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36384251)

  • 21. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
    Sim AJ; Jain MD; Figura NB; Chavez JC; Shah BD; Khimani F; Lazaryan A; Krivenko G; Davila ML; Liu HD; Falchook AD; Dahiya S; Rapoport AP; Kim S; Locke FL; Robinson TJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1012-1021. PubMed ID: 31175906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
    Locke FL; Miklos DB; Jacobson CA; Perales MA; Kersten MJ; Oluwole OO; Ghobadi A; Rapoport AP; McGuirk J; Pagel JM; Muñoz J; Farooq U; van Meerten T; Reagan PM; Sureda A; Flinn IW; Vandenberghe P; Song KW; Dickinson M; Minnema MC; Riedell PA; Leslie LA; Chaganti S; Yang Y; Filosto S; Shah J; Schupp M; To C; Cheng P; Gordon LI; Westin JR;
    N Engl J Med; 2022 Feb; 386(7):640-654. PubMed ID: 34891224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
    Kambhampati S; Saumoy M; Schneider Y; Serrao S; Solaimani P; Budde LE; Mei MG; Popplewell LL; Siddiqi T; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
    Blood; 2022 Nov; 140(19):2024-2036. PubMed ID: 35914220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review.
    Dimou M; Bitsani A; Bethge W; Panayiotidis P; Vassilakopoulos TP
    In Vivo; 2021; 35(6):3401-3406. PubMed ID: 34697175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.
    Kato K; Makita S; Goto H; Kanda J; Fujii N; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
    Int J Clin Oncol; 2022 Jan; 27(1):213-223. PubMed ID: 34599413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.
    Mian A; Wei W; Hamilton BK; Winter AM; Khouri J; Pohlman B; Gerds AT; Jagadeesh D; Anwer F; Kalaycio M; Dean RM; Sobecks R; Caimi PF; Hill BT; Majhail NS
    Bone Marrow Transplant; 2023 May; 58(5):590-593. PubMed ID: 36774431
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
    Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
    J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.
    Melody M; Gandhi S; Saunders H; Abdel-Rahman Z; Hastings J; Lengerke Diaz P; Gannon N; Truong T; Hathcock M; Khurana A; Johnston P; Ansell S; Bennani N; Paludo J; Bisneto JV; Wang Y; Rosenthal A; Foran J; Ayala E; Murthy HS; Roy V; Castro JE; Lin Y; Kharfan-Dabaja MA
    Leuk Lymphoma; 2022 Jun; 63(6):1363-1368. PubMed ID: 35109766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
    Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.
    Strati P; Varma A; Adkins S; Nastoupil LJ; Westin J; Hagemeister FB; Fowler NH; Lee HJ; Fayad LE; Samaniego F; Ahmed S; Chen Y; Horowitz S; Arafat S; Johncy S; Kebriaei P; Mulanovich VE; Ariza Heredia E; Neelapu SS
    Haematologica; 2021 Oct; 106(10):2667-2672. PubMed ID: 32732355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.
    Wudhikarn K; Bansal R; Khurana A; Hathcock MA; Bennani NN; Paludo J; Villasboas JC; Wang Y; Johnston PB; Ansell SM; Lin Y
    Blood Cancer J; 2021 Jul; 11(7):124. PubMed ID: 34210955
    [No Abstract]   [Full Text] [Related]  

  • 35. The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada.
    Hillis C; Vicente C; Ball G
    Pharmacoeconomics; 2022 Sep; 40(9):917-928. PubMed ID: 35844002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
    Plaks V; Rossi JM; Chou J; Wang L; Poddar S; Han G; Wang Z; Kuang SQ; Chu F; Davis RE; Vega F; Bashir Z; Jacobson CA; Locke FL; Reagan PM; Rodig SJ; Lekakis LJ; Flinn IW; Miklos DB; Bot A; Neelapu SS
    Blood; 2021 Sep; 138(12):1081-1085. PubMed ID: 34041526
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
    Jacobson CA; Locke FL; Ma L; Asubonteng J; Hu ZH; Siddiqi T; Ahmed S; Ghobadi A; Miklos DB; Lin Y; Perales MA; Lunning MA; Herr MM; Hill BT; Ganguly S; Dong H; Nikiforow S; Hooper M; Kawashima J; Xu H; Pasquini MC
    Transplant Cell Ther; 2022 Sep; 28(9):581.e1-581.e8. PubMed ID: 35609867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.
    Novo M; Ruff MW; Skrabek PJ; Lin Y
    Mayo Clin Proc; 2019 Nov; 94(11):2361-2364. PubMed ID: 31685159
    [No Abstract]   [Full Text] [Related]  

  • 40. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
    Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
    Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.